How IL-6 Affects TGFβ-Specific T Cells in Pancreatic Cancer
Author Information
Author(s): Maria Perez-Penco, Mikkel Byrdal, Lucia de la Torre, Marta Ballester, Shawez Khan, Majken Siersbæk, Inés Lecoq, Cecilie Oelvang Madsen, Julie Westerlin Kjeldsen, Inge Marie Svane, Morten Hansen, Marco Donia, Julia Sidenius Johansen, Lars Rønn Olsen, Lars Grøntved, Inna Markovna Chen, Luis Arnes, Morten Orebo Holmström, Mads Hald Andersen
Primary Institution: National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
Hypothesis
The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling.
Conclusion
Blocking IL-6R reduces the effectiveness of TGFβ-specific T cells in pancreatic cancer treatment.
Supporting Evidence
- IL-6R blockade hampered the development of vaccine-induced T-cells.
- Robust TGFβ-specific T-cell responses did not correlate with improved survival when IL-6R was blocked.
- Blocking IL-6R increased tumor-associated macrophage infiltration and an immunosuppressive phenotype.
- IL-6 levels were higher in tumor-conditioned media from mice treated with the TGFβ vaccine.
Takeaway
This study shows that IL-6 helps TGFβ-specific T cells fight pancreatic cancer, and blocking IL-6 can make the treatment less effective.
Methodology
The study used murine models and clinical data from pancreatic cancer patients to assess the role of IL-6 in TGFβ-specific immunity.
Potential Biases
Potential biases in patient selection and treatment response assessment.
Limitations
The study primarily focuses on murine models, which may not fully replicate human responses.
Participant Demographics
Patients with pancreatic cancer receiving immunotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website